Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab Neoadjuvant for Locally Advanced Cervical Cancer
NCT06055738Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in Cervical Cancer (CC), sponsored by Tangdu Hospital. Primary endpoint: Objective Response Rate. Started Oct 2023; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06055738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055738.